AMABELZ

Post-LOE

estradiol; norethindrone acetate

Teva

ANDAORALTABLET

Approved

Jun 2016

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

AMABELZ (estradiol; norethindrone acetate) by Teva is characteristics. Approved for moderate to severe vasomotor symptoms due to menopause (). First approved in 2016.

Drug data last refreshed 18h ago

$0.0BPart D

Mechanism of Action

characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in…

Indications (1)

moderate to severe vasomotor symptoms due to menopause ()

Worked on AMABELZ at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.